Lilly to present on leukemia/lymphoma Phase 3 data

 Results from BRUIN CLL-321 show Lilly's pirtobrutinib reduced the risk of disease progression or death by 46% compared to idelalisib plus rituximab or bendamustine plus rituximab

Pirtobrutinib prolonged the time to next treatment or death by a median of 23.9 months compared to 10.9 months in the control arm

BRUIN CLL-321 is the first randomized Phase 3 study in CLL ever conducted exclusively in patients previously treated with a BTK inhibitor

https://www.prnewswire.com/news-releases/phase-3-results-for-lillys-jaypirca-pirtobrutinib-in-covalent-btk-inhibitor-pre-treated-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-to-be-presented-at-the-2024-ash-annual-meeting-302326603.html